GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (HKSE:02616) » Definitions » Shares Outstanding (Diluted Average)

CStone Pharmaceuticals (HKSE:02616) Shares Outstanding (Diluted Average) : 1,251.8 Mil (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. CStone Pharmaceuticals's average diluted shares outstanding for the quarter that ended in Jun. 2023 was 1,251.8 Mil.


CStone Pharmaceuticals Shares Outstanding (Diluted Average) Historical Data

The historical data trend for CStone Pharmaceuticals's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals Shares Outstanding (Diluted Average) Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Diluted Average)
Get a 7-Day Free Trial 866.73 1,046.03 1,165.21 1,172.84 1,263.07

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,175.62 1,176.33 1,169.35 1,251.79 1,263.07

CStone Pharmaceuticals Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


CStone Pharmaceuticals  (HKSE:02616) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


CStone Pharmaceuticals Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


CStone Pharmaceuticals (HKSE:02616) Business Description

Industry
Traded in Other Exchanges
Address
218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123
CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.
Executives
Su Zhou Gong Ye Yuan Qu Zheng Ze Yuan Shi Chuang Ye Tou Zi Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Gong Ye Yuan Qu Zheng Ze Ji Ming Gu Quan Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Zheng Ze Jian Kang Chuang Ye Tou Zi Guan Li Zhong Xin You Xian He Huo 2501 Other
Su Zhou Gong Ye Yuan Qu Yuan He Yuan Dian Chuang Ye Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Guan Wei Hui 2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Jing Ji Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Yuan He Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Fei Jianjiang 2201 Interest of corporation controlled by you
Wuxi Healthcare Ventures Ii, L.p. 2101 Beneficial owner
Wuxi Healthcare Management, Llc 2201 Interest of corporation controlled by you
Morgan Stanley 2201 Interest of corporation controlled by you
Gic Private Limited 2102 Investment manager
Jiang Frank Ningjun 2307 Founder of a discretionary trust who can infl
Graceful Beauty Limited 2101 Beneficial owner
Boyu Capital Holdings Ltd. 2201 Interest of corporation controlled by you

CStone Pharmaceuticals (HKSE:02616) Headlines

No Headlines